debt_leverage_profile
Pre-revenue clinical-stage biotech; minimal debt, equity-funded; ~0x net leverage; 20% rate rise negligibly impacts burn rate
Inferred
Agent_Inference
interest_rate_sensitivity
Interest income on cash reserves slightly reduced; no meaningful debt service sensitivity; impact on NPV of pipeline discounted at higher WACC is moderate negative
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
API drug synthesis reliant on specialized chemistry CROs (likely China/India-based); single-source peptide/small-molecule inputs represent key chokepoints
Inferred
Agent_Inference
international_expansion_readiness
No meaningful international revenue; pre-commercial stage; sovereign currency devaluation exposure is effectively nil
Inferred
Agent_Inference
geographic_footprint
U.S.-only operations; no international revenue markets identified; currency devaluation exposure is negligible
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
High dependency on one or two CRO/CMO partners for preclinical/clinical manufacturing; substitution possible but costly and time-consuming
Inferred
Agent_Inference
business_model_type_primary
Clinical-stage drug development; no cloud-infrastructure-dependent revenue product; AWS termination would disrupt internal R&D tools only
Inferred
Agent_Inference
business_model_type_secondary
Biotech R&D / IP licensing model; cloud dependency is internal and non-revenue-critical; migration risk is low
Inferred
Agent_Inference
switching_cost_profile
Minimal API coupling risk; internal research software stack; primary switching cost is CRO/CMO transition, not cloud APIs
Inferred
Agent_Inference
howey_test_risk_index
Revenue model is grant/milestone/licensing-based; equity shares likely pass Howey Test as securities; no token or crypto element identified
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Limited patient data in early trials; GDPR/CCPA exposure low but growing as clinical trials expand; standard IRB and HIPAA protocols apply
Inferred
Agent_Inference
antitrust_exposure_flag
Negligible antitrust risk; pre-revenue niche therapeutic developer with no market dominance; orphan-drug focus further reduces exposure
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
~100% non-recurring; revenue composed of grants, milestone payments, and potential licensing deals; no subscription revenue
Inferred
Agent_Inference
monetization_vector
Milestone and licensing payments from pharma partners; potential future royalties on approved therapeutics
Inferred
Agent_Inference
pricing_architecture
No commercial pricing yet; future pricing will follow rare/specialty drug model (~$50K–$500K/year range); pricing power tied to clinical differentiation
Inferred
Agent_Inference
pricing_power_rating
Potentially high if pipeline targets orphan/rare disease indications with limited competition; dependent on Phase 2/3 outcomes
Inferred
Agent_Inference
target_gross_margin_bracket
Post-commercialization gross margins typical for biotech royalties/licensing: 70–90%; manufacturing-dependent products: 50–70%
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider risk; pre-commercial; IP protected by patents; grant funding non-dilutive and milestone-gated
Inferred
Agent_Inference
headcount_cost_structure
Headcount-sublinear at scale; clinical-stage company can expand via CRO outsourcing; internal headcount grows slowly relative to pipeline value
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of pipeline advancement is capital-intensive but not headcount-linear; CRO/CMO costs dominate incremental spend
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; no franchise model
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC equivalent is BD/licensing deal cost; pharma partnership deals cost $1M–$5M to execute; unit economics favorable if royalties >10%
Inferred
Agent_Inference
network_effect_present
No network effects; biotech drug development is inherently non-networked; value accrues through IP and clinical data exclusivity
Inferred
Agent_Inference
asset_efficiency_ratio
AI displacement risk low for core wet-lab/clinical operations; AI could accelerate target identification and reduce discovery costs modestly
Inferred
Agent_Inference
recession_resistance_tier
Moderate resilience; grant funding partially recession-proof; pharma licensing deals may slow in downturns; patient need is non-discretionary
Inferred
Agent_Inference
customer_segment_primary
Pharmaceutical/biotech licensing partners and collaborators seeking novel therapeutic mechanisms
Inferred
Agent_Inference
customer_segment_secondary
NIH/government grant agencies and non-dilutive funding bodies supporting early-stage research
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
Capital allocated to clinical trial advancement and IP development; no legacy infrastructure reallocation; all capex is future-state R&D
Inferred
Agent_Inference
sec_cik
Not determinable with confidence; Nok Therapeutics is a private or early-stage company with no confirmed SEC CIK on record
Inferred
Agent_Inference
ticker
No confirmed public ticker; if private, no discount analysis applicable; if newly listed, likely trades at steep discount to peak biotech comps given pre-revenue status
Inferred
Agent_Inference